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Abstract: The purpose of this paper was to outline the development of short peptide targeting of the
human prostate specific antigen (hPSA), and to evaluate its effectiveness in staining PSA in human
prostate cancer tissue. The targeting of the hPSA antigen by means of antisense peptide AVRDKVG
was designed according to a three-step method involving: 1. The selection of the molecular target
(hPSA epitope), 2. the modeling of an antisense peptide (paratope) based on the epitope sequence,
and 3. the spectroscopic evaluation of sense–antisense peptide binding. We then modified standard
hPSA immunohistochemical staining practice by using a biotinylated antisense peptide instead of
the standard monoclonal antibody and compared the results of both procedures. Immunochemical
testing on human tissue showed the applicability of the antisense peptide technology to human
molecular targets. This methodology represents a new approach to deriving peptide ligands and
potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals
and vaccines.
Keywords: neoplasm; prostate specific antigen; biomarker; antisense peptide; immunohistochemistry;
nanomedicine
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1. Introduction
Classic methods of cancer therapy combine surgery, chemotherapy, hormonal therapy and
radiation therapy [1]. Their main goal is the selective destruction of cancer cells, with minimization of
toxicity in non-target tissues [1]. Targeted therapies, based on small organic molecules or monoclonal
antibodies, have significantly improved the effectiveness of classic cancer therapy, while also being
less harmful to normal cells [2]. However, the development and production of such therapies is
often associated with high costs, with equally high costs in the application of therapy per individual
patient [1,3].
Only a small number of molecular markers was exploited for development of targeted therapies,
and one of the suggested approaches intended to improve production has been the use of small
peptides [4]. Theoretically, small peptides for targeting of tumor markers could be used to develop
a new generation of diagnostic and therapeutic substances [4,5]. Synthetic peptides have many
advantages in comparison to monoclonal antibodies, i.e., relatively simple and inexpensive synthesis,
stability and easy storage and transportation [6]. They show an absence of immunoreactivity, thus
minimizing allergic side-effects [7,8]. Their small size gives them favorable pharmacokinetic properties,
with better penetration to cancer tissue [5]. Ethical considerations are also significant, because the
production of synthetic peptides does not require the sacrifice of animals or the application of procedures
painful to them, in contrast to the production of monoclonal antibodies [9]. Peptides developed in
this manner could be used for the development of radiopharmaceuticals for the selective targeting of
primary and metastatic tumor markers, particularly useful in the detection of early metastases and
staging of the disease [4,5].
This methodology thus represents a promising new way of deriving peptide ligands and
potential lead compounds for the development of novel diagnostic substances, biopharmaceuticals
and vaccines [10–21]. A similar approach has been used in biomedicine for the efficient modeling of
more than 40 peptide–receptor systems; however, to our knowledge, immunohistochemical studies
involving selective antigen imaging with antisense peptides are not available [11–21]. Therefore, in this
paper we investigate whether a computationally derived short antisense peptide, targeting a selected
epitope of the human prostate specific antigen (hPSA) could be used in preference to the standard
monoclonal antibody for staining the PSA biomarker in human prostate cancer tissue [10–22].
2. Results and Discussion
The antisense peptide AVRDKVG was derived using amino acid pairing theory [5,19–21].
Following the selection of the molecular target (hPSA epitope), the potential peptide ligand was
designed using antisense peptide translation in the 3′ to 5′ direction, and its binding affinity, measured
as a dissociation constant (Kd) was evaluated [10–12,19–21]. The peptide ligand obtained, AVRDKVG,
was then biotinylated and used for hPSA immunohistochemical staining instead of the standard
monoclonal antibody. The results of both methods were compared and discussed.
2.1. Step 1: Selection of Molecular Target (hPSA Epitope)
Previously published studies involving epitope scanning, phage libraries and antibody binding
have shown that hPSA region, spanning from L50 to V65 (LLGRHSLFHPEDTGQV; Scheme S1),
represents a well-defined epitope recognized by anti-PSA monoclonal antibodies (mAbs) [23–26].
The results of four classic studies, presented in Table 1, show that the septapeptide RHSLFHP (red),
located in the region R53-P59 of hPSA, is a consensus epitope sequence [23–26].
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Table 1. Targeted epitope sequences of the human prostate specific antigen (hPSA) molecule, verified
in previous studies.
Targeted
Sequence Epitope Scanning Phage Library Antibody Study
GRHSLFHP 6mer 10mer B80 Jette et al. [23]
LLGRHSLFHPEDTGQV 15mer 17-1A2 Corey et al. [24]
RHSLFHP 15mer 6C8DS Michel et al. [25]
RHSLFHPEDTGQ 15mer, 8mer H164, 2Cl Piironen et al. [26]
This finding is confirmed by different computational methods. Table 2 shows that the consensus
of 10 epitope prediction servers, based on different physicochemical criteria [27–40], also points to the
RHSLFHP sequence as the most probable hPSA epitope [23–26]. The same result is obtained using
binding site prediction methods: Phyre2–3DLigandSite and RaptorX (Figure 1) [41–44]. The binding
site predicted by Phyre2–3DLigandSite is in the vicinity of residues R53 and S55 (Figure 1a), while that
predicted by RaptorX is close to R53, S55, H58 and P59 (Figure 1b). Therefore, hPSA epitope RHSLFHP
was used as a starting point for the construction of the antisense peptide, paratope in Step 2.
Table 2. Prediction of hPSA epitope RHSLFHP was obtained using 10 epitope prediction methods.
Server Epitope Prediction Method hPSA Epitope
1 Kyte and Doolittle (Hydrophobicity) RHSLFHPED
2 BcePred (Antigenic propensity) NKSVILLGRHSL
3 BepiPred-2 (Random forest detection) FHPED
4 LBtope (SVM & κ-NN detection) LGRHSLFHP
5 COBEpro (Epitopic propensity) PEDTGQV
7 Sann (Solvent accessibility) FHP
6 RVP-net (Solvent accessibility) RHS—-HP
8 NetTurnP (β-turn) RHSL
9 LEPS (β-turn) RHSLFH
10 Informational spectrum (ISM—EIIP) LFHPE
Frequency Consensus (>5) 111111226666677431111
NKSVILLGRHSLFHPEDTGQV
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Scheme 1. Twenty amino acids and three stop codons for the protein synthesis are specified by the 
genetic code, using sixty-four 3-letter codons (top). The number of antisense amino acids and related 
complementary pairs depends on the direction of codon translation (bottom) [19,20]. For the 
complementary (sense–antisense) pairs of the genetic code translated in a 3′ to 5′ direction r = 0.85, 
and for the complementary (sense–antisense) pairs of the genetic code translated in a 5′ to 3′ direction 
r = 0.86 (single linkage algorithm, Gower similarity index; PAST software 3.16). 
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2.2. Step 2: Modeling of Antisense Peptide AVRDKVG (hPSA Paratope)
The antisense peptide was designed using the translation of the hPSA epitope RHSLFHP in a 3′
to 5′ direction (Scheme 1) [19,20]. A 3′ to 5′ translation direction was employed since it produces fewer
antisense peptides (Scheme 1) [19,20].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 22 
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Table 3 illustrates the design of the antisense peptide AVRDKVG, obtained from the sense 
peptide epitope by the 3′ to 5′ translation of amino acid complementary pairs in Scheme 1 [19,20]. 
Potential antibody structures (paratopes) to hPSA epitope RHSLFHP were selected using the Basic 
Local Alignment Search Tool (BLAST), with the blastp, i.e., protein–protein, option [19,20,45]. The 
results presented in Table 3 show four antisense quadripeptide motifs detected in human antibody 
structures. The consensus (final) structure of the antisense peptide AVRDKVG was obtained as four 
linear paratope motifs AVRD, VRDK, RDKV and DKVG, selected on the basis of the highest score of 
antibody homologies detected by the BLAST search [19,20,45]. The predicted structures of the sense 
hPSA epitope RHSLFHP and its antisense paratope AVRDKVG using the PEPstrMOD method 
indicated extended structures that may facilitate binding (Figure 2, Schemes S3–S4) [11,14,46].  
Scheme 1. Twenty amino acids and three stop codons for the protein synthesis are specified by
the genetic code, using sixty-four 3-letter codons (top). The number of antisense amino acids and
related complementary pairs depends on the direction of codon translation (bottom) [19,20]. For the
complementary (sense–antisense) pairs of the genetic code translated in a 3′ to 5′ direction r = 0.85, and
for the complementary (sense–antisense) pairs of the genetic code translated in a 5′ to 3′ direction r =
0.86 (single linkage algorithm, Gower similarity index; PAST software 3.16).
Table 3 illustrates the design of the antisense peptide AVRDKVG, obtained from the sense
peptide epitope by the 3′ to 5′ translation of amino acid complementary pairs in Scheme 1 [19,20].
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Potential antibody structures (paratopes) to hPSA epitope RHSLFHP were selected using the Basic
Local Alignment Search Tool (BLAST), with the blastp, i.e., protein–protein, option [19,20,45]. The
results presented in Table 3 show four antisense quadripeptide motifs detected in human antibody
structures. The consensus (final) structure of the antisense peptide AVRDKVG was obtained as four
linear paratope motifs AVRD, VRDK, RDKV and DKVG, selected on the basis of the highest score
of antibody homologies detected by the BLAST search [19,20,45]. The predicted structures of the
sense hPSA epitope RHSLFHP and its antisense paratope AVRDKVG using the PEPstrMOD method
indicated extended structures that may facilitate binding (Figure 2, Schemes S3 and S4) [11,14,46].
Table 3. The antisense peptide sequence AVRDKVG was obtained by joining four paratopes one by
one. The paratopes motifs were selected on the basis of the highest number of antibody homologies
detected by the Basic Local Alignment Search Tool (BLAST) [45].
hPSA Epitope (aa 53–59) RHSLFHP Antibody Motifs (BLAST)
Paratope scan AVRD 8
VRDK 17
RDKV 10
DKVG 73
Antisense paratope (total) AVRDKVG 108
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2.3. Step 3: Spectroscopic Evaluation of Binding between Sense and Antisense Peptide
The affinity of epitope–paratope binding (Kd) was experimentally verified in Step 3 with tryptophan
fluorescence spectroscopy, microscale thermophoresis and magnetic particle enzyme immunoassay.
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2.3.1. Tryptophan Fluorescence Spectroscopy
The binding of hPSA peptide RHSLFHP and its antisense peptide AVRDKVG was evaluated by
means of tryptophan fluorescence spectroscopy [19,20,49]. Tryptophan was added to the C-terminus
of the antisense peptide (AVRDKVGW) to enable the fluorescence measurement. Singular value
decomposition analysis suggested only two spectrally active species, one of the antisense paratope
AVRDKVGW and the other of the complex of AVRDKVGW with its binding partner, RHSLFHP, since
RHSLFHP was not spectrally active in fluorescence mode. The results in Figure 3a, suggest a 1-to-1
complex formation, without any higher order complexes. This model is given by equations (1) and (2),
where Kd is the dissociation constant of the complex:
AVRDKVGW − RHSLFHP
 AVRDKVGW + RHSLFHP (1)
Kd =
[AVRDKVGW][RHSLFHP]
[AVRDKVGW–RHSLFHP]
(2)
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Figure 3. (a) Tryptophan fluorescence spectroscopy of the hPSA epitope RHSLFHP and its antisense
ligand AVRDKVGW. Insert: Fitting curve at 360 nm. (b) Microscale thermophoresis of the hPSA
epitope RHSLFHP and its antisense ligand Biotin-AVRDKVG.
The calculated dissociation constant (Kd) was 2.6 ± 0.19 µM (mean ± SEM), which indicates
acceptable binding affinity for the epitope–paratope or antigen–antibody interaction [19,20,49].
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2.3.2. Microscale Thermophoresis and Magnetic Particle Enzyme Immunoassay
Biotinylation of the antisense peptide ligand AVRDKVG is a practical modification that enables the
visualization of the ligand-acceptor complex with the secondary anti-biotin antibody (or streptavidin
polymer) conjugated to HRP [20,50]. Consequently, microscale thermophoresis was used to analyze
the binding of hPSA peptide RHSLFHP (residues 53–59) and its biotinylated antisense peptide
AVRDKVG [19,20,50–52]. The data, presented in Figure 3b, showed a single binding event in a
micromolar concentration range [19]. The dissociation constant of the complex was Kd = 24.3 ± 0.74 µM
(Figure 3b; mean ± SEM). This indicated that N-terminal biotinylation of antisense peptide AVRDKVG,
made for the purpose of immunohistochemical PSA staining, does not significantly alter the binding to
hPSA region 53–59 (RHSLFHP). The results of the microscale thermophoresis were confirmed by the
magnetic particle enzyme immunoassay (MPEIA), as shown in Figure 4.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  8 of 22 
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methods gave comparable results for th bindi g of hPSA epit pe RHSLFHP and its a tisense ligand
Biotin-AVRDKVG. The insignificant drop in the binding affinity, resulting from biotin modification of
the anti ens molecule, was still within the micro- to millimolar Kd range adequate for the antibodies
to exert their function [53–55]. hPSA epitope RHSLFHP that we used as a template for the antisense
peptide binder (Biotin-AVRDKVG) was located i the pitope region II [23–26]. This well-known
region of the PSA was exposed to the surface of the molecule, spanning from R53 to Q64 [23–26].
The specificity of the RHSLFHP binding was confirmed previously using anti-PSA mAbs and random
peptide libraries [23–26]. For this research, a mismatched peptide Biotin-EHFRW was used as a
negative control for the experimental design in Figure 4.
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The measured dissociation constant of Biotin-AVRDKVG in the low µM range was appropriate for
the most immunochemical applications, since weak affinity antigen–antibody recognition was shown
to be efficient even at Kd > 10−4 M [53–55]. Strandh et al. have shown that, in addition to antibodies,
surface plasmon resonance is also well suited for the low affinity Kd determination of small analytes
with mw <1000 [54,55].
Our results in Figures 3b and 4b confirm that microscale thermophoresis and MPEIA are also
applicable for this type of assay, since the sense (RHSLFHP) and antisense (Biotin-AKRDKVG) peptides
used in this study have the molecular masses of 893.02 and 970.15, respectively.
2.4. hPSA Immunohistochemistry with Biotynilated Antisense Peptide and Monoclonal Antibody
Direct testing of the antisense peptide binding to the hPSA molecule was carried out using human
tissue samples, with two methods involved in the staining of hPSA (Protocol 1 and Protocol 2, Figure 5):
The first staining protocol was based on standard immunohistochemistry using a primary antibody,
while the second method was a novel procedure based on a biotinylated antisense peptide instead of
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Figure 5. Two hPSA immunohistochemical staining protocols. The first is based on standard
immunohistochemistry using a primary antibody (Protocol 1), while the second method is a novel
procedure based on a biotinylated antisense peptide (Protocol 2).
Each protocol for PSA staining consisted of six steps. Steps 1, 4, 5 and 6 of protocol 1 and protocol
2 were identical, while steps 2 and 3 differed (Figure 5). In step 2 of protocol 2, a standard primary
antibody was replaced by an N-terminal biotinylated antisense peptide AVRDKVG. In step 3 of
protocol 2, the standard HRP-labelled polymer directed to the primary antibody was replaced by the
HRP conjugated anti-biotin antibody. Otherwise the procedures were identical. The details of both
protocols were presented in the Materials and Methods (Section 3.6). A comparison of these staining
protocols conducted on parallel samples of seven different patients showed very similar staining of the
hPSA antigen (Figure 6 and Table 4). Optimal antisense peptide dilution and standard monoclonal
antibody dilution were very similar (Figures 6, A2 and A3).
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Figure 6. (a1,b1,c1) Immunohistochemical staining of three different hPSA tissue samples with
standard monoclonal antibody ER-PR8 (dilution 1:100). (a2,b2,c2) Immunohistochemical staining of
three different hPSA tissue samples with biotinylated antisense peptide AVRDKVG (dilution 1:100).
The black line in the lower right corner denotes the scale bar (0.5 mm).
It was fir ed tha t e antisense peptide AVRDKVG is comparable to the standard primary
monoclonal mouse anti-hum n PSA antibody, with regard to the sig al to noise ratio [56,57]. The best
staining of the prostate cancer tissue was obtained with a dilution of 1:100, antisense peptide, which
yielded a solid staining signal with minimal or absent background noise (Figure 6, Figure A2, Figure A3
and Table 4). Dilutions 1:10 and 1:50 of the antisense peptide showed an increase in background noise,
while dilutions 1:200 and 1:500 were accompanied by a loss of staining signal (Table 4 and Figure A2).
The specimens were analyzed using the current standa ds for immunohistochemical quality control
(Table A2) [56,57], and the results are presented in Table 4. The overall quality of scoring according to
the NordiQC criteria was good (score 2) [57].
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Table 4. Quality control of hPSA staining with antisense peptide dilutions, based on NordiQC scoring
criteria: 0—Poor; 1—Borderline; 2—Good; 3—Optimal [57].
Patient No.\Dilutions * 1:10 1:50 1:100 1:200 1:500
1 0 1 2 0 0
2 0 1 2 1 0
3 0 2 3 1 0
4 0 1 2 1 0
5 0 1 3 1 0
6 0 1 2 1 0
7 0 1 2 1 0
Sum of scores 0 8 16 6 0
* The column with the largest scores is marked red.
It was not possible to perform the comparative analysis of PSA binding sites for Biotin-AVRDKVG
antisense peptide and standard mouse-anti human PSA mAb ER-PR8 (Dako, Glostrup, Denmark), both
used in this study for the immunohistochemistry (IHC) staining, since the location of ER-PR8 antibody
epitope could not be established [58,59]. hPSA antisense Biotin-AKRDKVG, did not stain negative
tissue control (liver), and its mismatched peptide Biotin-EHFRW and CD20 monoclonal antibody
did not stain hPSA of the prostate tissue (Figure 7). Negative controls in Figure 7c1–c3 confirm the
“technical specificity” of an IHC stain with Biotin-AKRDKVG, because there were no “false-positive
reactions” in negative control tissue (liver tissue) [60]. For IHC performed on hPSA tissue section,
“technical sensitivity” was demonstrated by evaluation of the intensity of the “stain reaction” (from
weak to strong) in Table 4, Figures A2 and A3 [60].
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Figure 7. (a1, a2, a3) Negative control peptide: Immu ohistochemistry (IHC) staining of the prostate
tissue with a peptide Biotin-EHFRW that does not bind to hPSA epit pe RHSLFHP. (b1, b2, b3)
Negative control antibody—prostate tissue: IHC staining with CD20 (L26) monoclonal antibody; only
inflammatory cells are stained. (c1, c2, c3) Negative control tissue—liver tissue: IHC staining with the
antisense paratope Biotin-AVRDKVG that binds to hPSA epitope RHSLFHP. Scale bar = 0.5 mm.
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The results of this study suggest that antisense peptides could be used to target a specific human
tumor biomarker, i.e., hPSA.
2.5. Concluding Remarks
Tryptophan fluorescence spectroscopy, microscale thermophoresis and magnetic particle enzyme
immunoassay proved to be useful methods for determining the binding affinities of antisense peptides
to their targets. Tryptophan fluorescence spectroscopy and microscale thermophoresis are simple,
quick, inexpensive and could be used for high-throughput screening [19,20,49,51,52]. The combination
of these methods with computational procedures for ligand-acceptor modeling and design enables
the quick and simple selection of the antisense peptide structures, which can be used for further
development [19,20,27].
Our data suggest that selective targeting of tumor antigens could be achieved by using antisense
peptides. This technology possesses certain advantages and disadvantages with respect to monoclonal
antibodies. The most prominent difference is the small size of antisense peptides in comparison with
antibodies. This property is very important for the depth of tissue penetration, especially in situations
where peptide is intended to be used as a carrier, e.g., for radiopharmaceuticals or radiocontrast
agents [5]. The Kd measurements for the hPSA antisense peptide used in our protocols is in the range
of micromoles, whereas the value for monoclonal antibodies is in the nano- to micromolar range [61].
This suggests that maximum care must be applied to the selection of peptides with optimal affinity, i.e.,
the lowest possible Kd value. It is important to note that too high an affinity can, paradoxically, reduce
the tissue penetration of antibodies [61]. In situations like this, very high-affinity antibodies will bind to
targets near blood vessels (Figure 8), especially where the number of targets is high. This suggests that
fluorescence spectroscopy, microscale thermophoresis and/or magnetic particle enzyme immunoassay
should play a crucial role in the development of antisense peptide use, due to the fast, simple and
inexpensive determination of Kd value.
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Immunohistochemical staining is a logical step further in the use of antisense peptides, because
it establishes selectivity in binding, especially in comparison with monoclonal antibody binding,
which can be used as a gold standard. Immunochemical testing on hu an tissue directly shows
the applicability of the antisense peptide technology to human molecular targets. The methodology
of this preliminary study did not include pharmacokinetics, which is required for the development
of diagnostic and therapeutic substances. Nevertheless, selected antisense peptides are potential
lead compounds for the development of novel diagnostic, prognostic and therapeutic substances,
biopharmaceuticals and vaccines [19,20].
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3. Materials and Methods
3.1. Software Tools Used for Epitope and Ligand Binding Site Determination
In silico prediction of the linear hPSA epitope RHSLFHP was carried out using the consensus result
of 10 servers presented in Table 2: ExPASy–ProtScale (Kyte & Doolittle hydropathy scale, window size
9), BcePred (antigenic propensity method), BepiPred-2 (random forest regression algorithm), LBtope
(support vector machine models), SCRATCH–COBEpro (support vector machine based propensity
score; Scheme S1), Sann and RVP-net (solvent accessibility algorithms), NetTurnP and LEPS (β-turn
determination) and the informational spectrum method based on electron-ion interaction potential
(ISM-EIIP) [27–40]. The hPSA sequence is given in Scheme S1.
The 3D structures of the hPSA molecule and its binding sites were predicted by coupled
Phyre2–3DLigandSite servers for protein modeling, prediction and analysis (Figure 1a) [41,42]. 100%
of hPSA residues were modeled at >90% confidence, the 3D structure template, obtained with X-ray
diffraction, was protein data bank (PDB) file 2ZCH chain P (Scheme S2) [41]. The results obtained by
Phyre2–3DLigandSite-based prediction were confirmed by RaptorX web portal Binding Prediction
(Figure 1b) [44].
The antisense peptide, i.e., paratope AVRDKVG, was designed by the translation of the RHSLFHP
epitope in a 3′ to 5′ direction (Scheme 1) [19,20]. Potential paratopes to hPSA53–59 epitope were selected
using BLAST, with the blastp quadripeptide option (protein–protein BLAST) [19,20,45].
The 3D structures of the sense epitope RHSLFHP (Scheme S3) and its antisense paratope AVRDKVG
Scheme S4), presented in Figure 2, were modeled using PEPstrMOD method [46]. The PDB files were
visualized using CCP4 software version 7.0 [62].
Protein–peptide interactions between hPSA and its antisense peptide AVRDKVG were investigated
using the pepATTRACT and CABS-dock web servers [47,48]. Both web services required the hPSA
(protein) input file in PDB format (Scheme S2) and docking peptide sequence (AVRDKVG).
The pepATTRACT server is a novel fully blind docking protocol that does not require any
information about the binding site [47]. In a very short time (~10 min) this web server returns an
analysis of the most prevalent protein–peptide contacts among the top 50 generated models [47].
The pepATTRACT protocol is well tuned to assist users to identify the binding site, performs large-scale
in silico experiments, and represents a useful starting point to rationalize the design for further
protein–peptide docking experiments [47]. Model No. 24, presented in Figure A1a, is a precise
description of hPSA–AVRDKVG docking. Results are given in PDB format as above (Scheme S5).
The CABS-dock server enables the modeling of protein–peptide interactions through an efficient
method for the flexible docking of peptides to proteins without pre-defining the localization of the
binding site [48]. The CABS-dock protocol was tested over the largest dataset of non-redundant
protein–peptide interactions available to date, which includes bound and unbound docking cases [48].
Using a ligand RMSD cutoff of 5.5 Å, the best 10 models are selected with reference to the quality of
docking models, which represent low-to-medium-accuracy models [48]. Model No. 5, presented in
Figure A1b and Table A1, gives a precise description of hPSA–AVRDKVG docking. This result was
given in the PDB format as Scheme S6.
3.2. Peptides Used in Experiments
1. Human prostate specific antigen (hPSA) peptide 53–59: RHSLFHP (mw 893.02, >97% purity,
GenScript, Piscataway, NJ, USA).
2. C-terminal tryptophan antisense peptide: AVRDKVGW (mw 930.07, >97% purity, GenScript,
Piscataway, NJ, USA).
3. N-terminal biotin antisense peptide: Biotin-AVRDKVG (mw 970.15, >97% purity, GenScript,
Piscataway, NJ, USA).
4. N-terminal biotin peptide: Biotin-EHFRW (mw 1000.14, >97% purity, GenScript, Piscataway, NJ, USA).
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3.3. Tryptophan Fluorescence (Binding of hPSA Epitope RHSLFHP and its Antisense Peptide)
The fluorescence spectra of the sense and antisense peptides, and their complexes, were measured
at 25 ◦C by OLIS RSM 1000F spectrofluorimeter (Olis, Inc., Bogart, GA, USA) equipped with a
thermostatted cell holder. The excitation wavelength was 280 nm (Figure 3a) [19,20,49]. The antisense
peptide AVRDKVGW became bound to the hPSA peptide RHSLFHP, and their complex exhibited
fluorescence, whereas the ligand RHSLFHP did not. The fluorescence units in Figure 3a are given
as a ratio of signals obtained from sample and reference photomultiplier tubes (PMTs). SPECFIT
software was used to analyze data obtained from the titrations [19,20,49]. The titration curve, in
Figure 3a—Insert: Fitting curve at 360 nm, shows a good fit to data (r2 = 0.947). The dissociation
constant was 2.6 ± 0.19 µM (Kd = mean ± SEM).
3.4. Microscale Thermophoresis (Binding of hPSA Epitope RHSLFHP to its Antisense Peptide)
The binding between the biotinylated antisense peptide AVRDKVG and a titrant, i.e., hPSA peptide
RHSLFHP (Figure 3b), was observed by the method of microscale thermophoresis (MST) [19,20,51,52].
MST-analysis was performed using the Monolith.NT.115 instrument (NanoTemper Technologies
GmbH, Munich, Germany). Biotin-AVRDKVG antisense directed to the hPSA region 53–59 was labeled
with DY-495 (Red). The labeling procedure and the subsequent removal of unattached dye were
performed within 45 min. A serial dilution of the non-labeled hPSA titrant was prepared in a 10 mM
phosphate buffer. The concentration of biotin-hPSA antisense labelled with DY-495 was kept constant,
while the concentration of the non-fluorescent binding partner (hPSA peptide RHSLFHP53–59) was
varied between 0.0854 µM and 2.8 mM. After a short incubation, the samples were loaded into MST
NT.115 standard glass capillaries and the MST-analysis was performed [19,20,51,52]. The data were
analyzed using GraphPad Prism software version 5. The titration curve shows a good fit to data
(r2 = 0.989), Kd = 24.3 ± 0.74 µM (mean ± SEM).
3.5. Magnetic Particle Enzyme Immunoassay (Binding of hPSA Epitope RHSLFHP and its Antisense Peptide)
SPHERO™ Carboxyl Magnetic Particles (2.5% w/v, 1.14 µm) were coated with hPSA peptide
(RHSLFHP) using a slightly modified one step 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
coupling method suggested by manufacturer [20,50]. Briefly, the reaction mixture was composed of
2 mL sodium acetate buffer (0.01M, pH 5.0), 2 mg of peptide and 2 mL of 2.5% w/v carboxyl magnetic
particles—1.14 µm, 20 mg of EDC. Reactions proceeded in glass reaction tubes overnight at room
temperature in a rotary mixer. Tubes were centrifuged at 3000× g for 15 min, supernatant was carefully
discarded, and the pellets were washed twice in 4 mL isotonic buffered saline (IBS), followed by
centrifugation [20,50]. After washing, coated magnetic particles were resuspended in 4 mL of PBS
containing 0.05% Tween 20.
Two folds serial dilutions (1.09–70 µM) of biotinylated antisense peptide AVRDKVG were made in
96-well microtiter plates to generate standard curves (Figure 4b). Mismatched peptide Biotin-EHFRW
was used as a negative control (Figure 4b). A suspension (1.25% w/v) of carboxyl magnetic particles,
coated with sense peptide RHSLFHP, was added to each well (40 µL/well) [20,50]. The plates were
incubated at room temperature for 30 min and washed with PBS-Tween 20 five times. The washing
solution was removed each time using the Spherotech UltraMag Separator (Sperotech, Inc., Lake Forest,
IL, USA).
A blocking solution (PBS with 1% BSA) was added to the wells and incubated at room temperature
for one hour. Wells were washed (PBS with 0.05% Tween 20) and ultrasensitive streptavidin-peroxidase
polymer conjugate, diluted in the ratio 1:200 in PBS with 0.05% Tween 20, was added to the wells and
incubated at room temperature for one hour (S 2438, SIGMA®, Saint Louis, MO, USA). Wells were
washed five times using PBS with 0.05% Tween 20. SIGMAFAST™ OPD solution (o-phenylenediamine
dihydrochloride) was added to the wells and incubated, in the dark, for 30 min at room temperature.
The absorbances were read at 450 nm on a multiwell plate reader. The data were analyzed using
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GraphPad Prism software version 5. The titration curve in Figure 4b shows a good fit to data with r2 =
0.996, and Kd = 24.6 ± 0.20 µM (mean ± SEM).
3.6. Immunohistochemical Staining of hPSA: Protocol 1 and Protocol 2
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of the University Hospital Centre Zagreb, No. 01-20/32-1-2006
(approved 28 February 2006). The project code of the Croatian Ministry of Science and Education
was 098-0982929-2524.
Immunohistochemistry was performed on deparafinized slides (xylen and a series of ethanol
solutions) at room temperature (20–25 ◦C). The phosphate-buffered saline (PBS) was used, with a
pH of 7.2 and containing disodium hydrogen phosphate, sodium chloride, potassium chloride and
potassium dihydrogen phosphate was used. PBS stock solution: 4 g KH2PO4, 23 g Na2HPO4, 4 g KCl,
160 g NaCl and 810 mL distilled water. Before staining, 100 mL of stock solution was diluted with
1900 mL of distilled water.
All slides (from seven patients) were selected from the repository of prostate cancer tissue, with
diagnosis confirmed by consensus of two independent pathologists. The two pathologists who
examined the slides stained with antisense peptides were unconnected with the pathologists who
established the initial diagnosis.
Each of the two immunohistochemistry protocols for PSA staining consisted of six steps. Steps 1,
4, 5 and 6 of protocol 1 and protocol 2 were identical, while steps 2 and 3 differed (Figures 5 and 6).
For this study, the slides were kept in the dark at room temperature (20–25 ◦C), to prevent fading as a
result of exposure to strong light. They were analyzed using an Olympus BX41 microscope, with an
Olympus DP71 camera set to three levels of magnification: less than 40×, 100×, and 500×.
3.6.1. Protocol 1 (Standard IHC Staining Technique)
Staining protocol 1 is a standard IHC staining technique using commercially available kit from
Dako (Dako EnVision+System-HRP (AEC), Glostrup, Denmark) and primary monoclonal mouse
anti-human PSA antibody. The kit and primary mouse antibody are intended for the quantitative
identification of hPSA by light microscopy (Figure 5). For this study the endogenous peroxidase
activity was first quenched by incubating the specimen with Dako’s Peroxidase block (step 1). Then,
the specimen was incubated with diluted mouse primary antibody, followed by incubation with the
HRP labeled polymer conjugated to goat anti-mouse immunoglobulins—steps 2 and 3, respectively.
The staining was completed by incubation with AEC + substrate-chromogen (step 4), followed by
hematoxylin counterstain and mounting—step 5 and 6, respectively. The negative control was the
primary monoclonal mouse anti-human CD20 (Clone L26; Dako, Glostrup, Denmark).
IHC staining—protocol 1 was performed in accordance with the manufacturer’s instruction, as
follows:
1. The specimen was covered with peroxidase block, i.e., 100 µL of 0.03% hydrogen peroxide
containing sodium azide (Dako, Glostrup, Denmark), and incubated for four minutes. Following
this procedure, the specimen was gently rinsed with phosphate buffered saline (PBS), and placed
in a fresh buffer bath.
2. Primary monoclonal mouse anti-human PSA antibody (Clone ER-PR8, Code M0750; Dako,
Glostrup, Denmark) was diluted with standard diluent containing 0.05 mol/L TRIS-HCl buffer
and a 1% bovine serum albumin (BSA). 100 µL of primary antibody diluted in the proportion
1:100 was used to cover the specimen. After 30 min of incubation at room temperature, the
specimen was gently rinsed with PBS and placed in a fresh buffer bath.
3. 100 µL of HRP-labelled polymer conjugated to goat anti-mouse immunoglobulins in Tris-HCl
buffer containing stabilizing protein and an anti-microbial agent (Dako, Glostrup, Denmark) was
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applied to cover the specimen, followed by a 30 min incubation. After 30 min of incubation, the
specimen was gently rinsed with PBS and placed in a fresh buffer bath.
4. The specimen was covered with 100 µL of AEC + substrate-chromogen solution for 10 min, i.e.,
3-amino-9-ethylcarbazole containing hydrogen peroxide, stabilizers, enhancers and anti-microbial
agent (Dako, Glostrup, Denmark). After that period the specimen was again rinsed with PBS.
5. The slides were immersed in a bath of aqueous hematoxylin (Mayerr’s hematoxylin), and rinsed
gently in a distilled water bath. Slides were dipped 10 times into a bath of ammonia (0.037 mol/L),
and rinsed in a bath of distilled water for four minutes.
6. The specimens were mounted and coverslipped with the non-aqueous permanent mounting
medium Ultramount.
3.6.2. Protocol 2 (Modified IHC Staining Using Antisense Peptide Instead of Primary Antibody)
The staining protocol 2 was a modified IHC protocol 1, as follows: In step 2 we used antisense
peptide Biotin-AVRDKVG, instead of the primary monoclonal mouse anti-human PSA antibody, in
step 3 we used rabbit polyclonal antibody to biotin conjugated to HRP, instead of HRP labeled polymer
conjugated to goat anti-mouse immunoglobulins (Figure 5), with peptide Biotin-EHFRW as a negative
control (Figure 7). Otherwise, the procedures and chemicals were identical. Quality control for the
PSA staining was investigated using NordiQC scoring criteria [57]: 0—Poor; 1—Borderline; 2—Good;
3—Optimal. The scale is presented in Table A2, and the final results given in Table 4 are expressed as a
sum of scores.
IHC staining—protocol 2:
1. The specimen was covered with peroxidase block, i.e., 100 µL of 0.03% hydrogen peroxide
containing sodium azide (Dako, Glostrup, Denmark), and incubated for four minutes. Following
this, the specimen was gently rinsed with phosphate buffered saline (PBS), and placed in a fresh
buffer bath.
2. Biotinylated antisense peptide AVRDKVG (GenScript, Piscataway, NJ, USA) directed to PSA
epitope 53–59 (RHSLFHP) was used to cover the specimen. Five milligrams of Biotin-AVRDKVG
antisense was diluted in 2.5 mL PBS. Dilutions 1:10, 1:50, 1:100, 1:200 and 1:500 were applied to
cover the specimen. A 100 µL volume was used per section. After 30 min of incubation, each
specimen was gently rinsed with PBS and placed in a fresh buffer bath.
3. Anti-biotin antibody conjugated to HRP (ab34645, Abcam, Cambridge, UK) was applied to cover
the specimen. Of the antibody 10 mg/2 mL was diluted 1:100. One hundred microliters of the
diluted antibody was applied to cover each specimen, followed by a 30 min incubation. After the
incubation, the specimen was gently rinsed with PBS and placed in a fresh buffer bath.
4. The specimen was covered with 100 µL of AEC + substrate-chromogen solution for 10 min,
i.e., 3-amino-9-ethylcarbazole containing hydrogen peroxide, stabilizers, enhancers and an
anti-microbial agent (Dako, Glostrup, Denmark). After that period the specimen was again rinsed
with PBS.
5. The slides were immersed in a bath of aqueous hematoxylin (Mayerr’s hematoxylin), and rinsed
gently in a distilled water bath. The slides were dipped 10 times into a bath of ammonia
(0.037 mol/L), and then rinsed in a bath of distilled water for four minutes.
6. The specimens were mounted and coverslipped with non-aqueous permanent mounting
medium Ultramount.
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s1.
Author Contributions: Conceptualization, N.Š. and P.K.; Formal analysis, N.Š. and P.K.; Funding acquisition,
N.Š.; Investigation, N.Š., P.K., P.T., H.Š., G.A., D.B., S.S., Ž.K., R.N.K., P.W., J.B.Ž., A.G.G. and M.G.; Methodology,
N.Š.; Project administration, N.Š.; Resources, N.Š., P.K., P.T., H.Š., G.A., D.B., S.S., Ž.K., R.N.K., P.W., J.B.Ž. and
Int. J. Mol. Sci. 2019, 20, 2090 16 of 20
M.G.; Supervision, N.Š. and P.K.; Validation, N.Š., P.K., P.T., R.N.K., P.W., J.B.Ž. and M.G.; Visualization, N.Š., P.K.,
P.T. and M.G.; Writing—original draft, N.Š. and P.K.; Writing—review & editing, N.Š. and P.K.
Acknowledgments: The support of the Croatian Ministry of Science and Education is gratefully acknowledged
(grant No. 098-0982929-2524).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
BLAST Basic Local Alignment Search Tool
hPSA Human Prostate Specific Antigen
HRP Horseradish Peroxidase
IHC Immunohistochemistry
Kd Dissociation Constant
mAb Monoclonal Antibody
MPEIA Magnetic Particle Enzyme Immunoassay
MST Microscale Thermophoresis
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Table A1. Amino acid pairs of the receptor (blue)–peptide (red) complex, at a distance closer than 4.5 Å,
predicted by CABS-dock server for flexible protein–peptide docking [48].
hPSA Region 53–60 (RHSLFHPE) Antisense Ligand (AVRDKVG)
L 56 V6, G7
H 58 D4, V6, G7/R3
E 60 7
3 Å ≤ RMSD (distance) ≤ 5.5 Å = medium-quality prediction.
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Table A2. NordiQC scoring c teria which include staining inte sity, signal-to-noise ratio, background
staining, aberrant staining pattern, counterstaining and preservation of morphology [57].
Score Criteria
Optimal (3) Staining reaction considered perfect or close to perfect.
Good (2) Staining reaction considered fully acceptable. The protocol may beoptimized to ensure the best staining intensity and signal-to-noise ratio.
Borderline (1) Staining considered insufficient.
Poor (0) Staining considered very insufficient.
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